Researchers are set to unveil groundbreaking findings that could revolutionize cancer treatment, from personalized cancer vaccines to novel therapies for patients whose cancer has progressed despite existing treatments. With the European Society for Medical Oncology (ESMO 2026) annual conference just days away, the spotlight is on relapse prevention, slowing cancer progression, and mitigating side effects.
Industry insiders report that ESMO 2026 will convene from October 23 to 27 in Madrid, Spain. Pharmaceutical giants like MSD, Moderna, and Pfizer, along with domestic firms, will present their latest anticancer research.
MSD and Moderna are slated to reveal Phase 3 results for their combination therapy of the personalized cancer vaccine ‘Intismeran Autogen’ and the immunotherapy drug Keytruda in melanoma patients.
This mRNA-based therapeutic vaccine is custom-designed to match the genetic profile of a patient’s tumor. It aims to train immune cells to recognize and attack cancer cells, potentially reducing post-surgery recurrence risk.
The Phase 3 trial enrolled 1,137 patients with Stage 2B to 4 melanoma who had undergone complete tumor resection. In August, the companies announced that the combination therapy significantly outperformed Keytruda alone in improving both relapse-free and distant metastasis-free survival.
The medical community is now eager to see the specific improvement metrics. Key data points include the reduction in relapse and mortality risk, the proportion of patients remaining recurrence-free, and the duration of follow-up. Rates of severe adverse events and treatment discontinuation due to side effects will also be crucial indicators.
A previous Phase 2B trial with five-year follow-up showed a 49% decrease in relapse and mortality risk compared to Keytruda monotherapy. However, this Phase 3 trial is distinct, and further validation of survival benefits is needed.
Pfizer will showcase Phase 2 results for its breast cancer drug candidate ‘Atrimociclib.’ The study focuses on hormone receptor-positive, HER2-negative advanced or metastatic breast cancer patients whose disease progressed after treatment with existing CDK4/6 inhibitors.
This drug selectively targets CDK4, a protein involved in cancer cell proliferation. The presentation will detail its efficacy and safety profile when combined with the anti-hormonal drug fulvestrant. There’s significant interest in its potential effectiveness following prior drug treatments.
Another area of focus is immunotherapy-only approaches that bypass chemotherapy. MSD will present Phase 3 results comparing Keytruda monotherapy to chemotherapy in patients with advanced or recurrent endometrial cancer with defects in DNA mismatch repair.
MSD reported in July that Keytruda significantly extended progression-free survival compared to chemotherapy. The upcoming presentation will provide detailed efficacy and safety data. However, the impact on overall survival remains under investigation, with further follow-up required.
On the domestic front, LigaChem Biosciences will present two studies on its antibody-drug conjugate (ADC) candidate LCB02A, which targets the claudin 18.2 protein in gastric and pancreatic cancers. The company will showcase preclinical efficacy and safety data, along with the design of its global Phase 1 and 2 trials.
SillaJen will present a poster on the Phase 1 study of its anticancer candidate BAL0891 in patients with advanced solid tumors. The presentation will cover safety and efficacy data for BAL0891 both as a monotherapy and in combination with the chemotherapy agent paclitaxel.
